Viiv Healthcare UK Limited — Sponsor Intelligence | 11 EU Trials

Filter these 11 trials by condition, phase, country and more.

Open in Search →

11 Registered trials

0 Recruiting

11 Completed trials

14 Countries active

10 Unique IMPs

100% Results reported

Phase III

Phase II

Phase I (Other)

Phase III: 5 Phase II: 4 Phase I (Other): 2

Oversight events:

3 temporary halts across 1 trial

View oversight register →

100%

11 of 11 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top IMPs

LAMIVUDINE, DOLUTEGRAVIR SODIUM 4 CABOTEGRAVIR 2 EMTRICITABINE, TENOFOVIR ALAFENAMIDE, BICTEGRAVIR 2 RILPIVIRINE 2 VH4524184 2 EMTRICITABINE, TENOFOVIR ALAFENAMIDE 1 FOSTEMSAVIR 1 GSK3739937 1 GSK4004280 1 GSK4011499 1

All trials

11 total

Mass Balance and Absolute Oral Bioavailability of [14C]VH4524184 Pending

2026-525590-40-00 Phase I (Other) 1 country
A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons with HIV-1 (INNOVATE Study) Ended

2025-521918-26-00 Phase II 7 countries EMTRICITABINE, TENOFOVIR ALAFENAMIDE; LAMIVUDINE, DOLUTEGRAVIR SODIUM; VH4524184
An exploratory study to investigate the impact on the viral reservoir of adding a broadly neutralizing antibody with or without an attachmen… Ended

2025-520629-19-00 Phase I (Other) 4 countries
PH 3b, CAB + RPV in people with suboptimal response to oral ART (CROWN) Ended

2024-515070-28-00 Phase III 5 countries CABOTEGRAVIR; RILPIVIRINE
A study to investigate the safety and efficacy of fostemsavir in heavily treatment experienced people living with HIV-1 resistant to other d… Ended

2024-513930-39-00 Phase III 1 country FOSTEMSAVIR
A study to evaluate the efficacy, safety, and tolerability of using an oral once-daily 2 drug regimen compared to an oral once-daily 3 drug … Ended

2023-504993-40-00 Phase III 11 countries EMTRICITABINE, TENOFOVIR ALAFENAMIDE, BICTEGRAVIR; LAMIVUDINE, DOLUTEGRAVIR SODI…
PH2a, VH4524184 Proof-of-Concept in Treatment-Naïve Adults Living with HIV-1 Ended

2023-507173-18-00 Phase II 2 countries VH4524184
PH2a, VH3739937 Proof-Of-Concept in TN HIV-1 Infected Adults Ended

2023-505780-37-00 Phase II 4 countries GSK3739937
Proof of concept treatment study of orally administered VH4004280 or VH4011499 in HIV-1 infected adults Ended

2023-505350-18-00 Phase II 4 countries GSK4004280; GSK4011499
A study to evaluate the efficacy, safety, participant choice and preference of an oral once-daily regimen or a long-acting injectable regim… Ended

2023-503893-19-00 Phase III 4 countries CABOTEGRAVIR; LAMIVUDINE, DOLUTEGRAVIR SODIUM; RILPIVIRINE
Ph 3b, BIC/FTC/TAF to DTG/3TC FDC, 96 Week switch, efficacy, safety, and tolerability study in ART-experienced older adults living with HIV … Ended

2022-503137-66-00 Phase III 8 countries EMTRICITABINE, TENOFOVIR ALAFENAMIDE, BICTEGRAVIR; LAMIVUDINE, DOLUTEGRAVIR SODI…

Showing 1–11 of 11 trials

← All sponsors A–Z